NPPB and type 2 diabetes mellitus: Average levels of NT-proBNP did not differ significantly between dapagliflozin and placebo groups after 6 or 12 weeks (p=0.43). Dapagliflozin group improvement in health status: Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) score (≥5-point increase) (p=0.039) OR ≥20% reduction in NT-proBNP levels. Positive effects of dapagliflozin were observed in patients with and without T2DM.